TY  - JOUR
AU  - Elliott, Perry
AU  - Gundapaneni, Balarama
AU  - Sultan, Marla B
AU  - Ines, Monica
AU  - Garcia-Pavia, Pablo
PY  - 2023
DO  - 10.1002/ejhf.2974
UR  - http://hdl.handle.net/20.500.12105/16395
AB  - AIMThe value of disease-modifying therapies (such as tafamidis) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and severe heart failure symptoms has been debated. This study assessed long-term all-cause survival in patients with New...
LA  - eng
PB  - Elsevier
TI  - Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms.
TY  - journal article
ER  -